EP0687308A4 - Recombinant epstein-barr viral capsid antigen useful in diagnostic method - Google Patents

Recombinant epstein-barr viral capsid antigen useful in diagnostic method

Info

Publication number
EP0687308A4
EP0687308A4 EP94910134A EP94910134A EP0687308A4 EP 0687308 A4 EP0687308 A4 EP 0687308A4 EP 94910134 A EP94910134 A EP 94910134A EP 94910134 A EP94910134 A EP 94910134A EP 0687308 A4 EP0687308 A4 EP 0687308A4
Authority
EP
European Patent Office
Prior art keywords
ebv
viral capsid
recombinant
capsid antigen
diagnostic method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94910134A
Other languages
German (de)
French (fr)
Other versions
EP0687308A1 (en
Inventor
Ramesh K Prakash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actavis Laboratories UT Inc
Original Assignee
Theratech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratech Inc filed Critical Theratech Inc
Publication of EP0687308A1 publication Critical patent/EP0687308A1/en
Publication of EP0687308A4 publication Critical patent/EP0687308A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C07K4/02—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Recombinant EBV-gp125 protein is made in a baculovirus expression system in sufficient quantity and purity to enable its use in assays such as ELISAs for quantitative detection of EBV VCA-IgG and VCA-IgM antibodies. The recombinant gp125 protein is similar in size to EBV-gp125 viral capsid antigen isolated from EBV-infected human cell lines, and has similar sensitivity and specificity in immunological assays for VCA-Ig antibodies.
EP94910134A 1993-02-23 1994-02-23 Recombinant epstein-barr viral capsid antigen useful in diagnostic method Withdrawn EP0687308A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2195193A 1993-02-23 1993-02-23
US21951 1993-02-23
PCT/US1994/001775 WO1994019495A1 (en) 1993-02-23 1994-02-23 Recombinant epstein-barr viral capsid antigen useful in diagnostic method

Publications (2)

Publication Number Publication Date
EP0687308A1 EP0687308A1 (en) 1995-12-20
EP0687308A4 true EP0687308A4 (en) 1997-07-09

Family

ID=21807030

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94910134A Withdrawn EP0687308A4 (en) 1993-02-23 1994-02-23 Recombinant epstein-barr viral capsid antigen useful in diagnostic method

Country Status (6)

Country Link
EP (1) EP0687308A4 (en)
JP (1) JPH08507681A (en)
KR (1) KR960701218A (en)
AU (1) AU674936B2 (en)
CA (1) CA2150691A1 (en)
WO (1) WO1994019495A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130115207A1 (en) * 2010-04-09 2013-05-09 The General Hospital Corporation Methods for the treatment of autoimmune diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3706233A1 (en) * 1987-02-26 1988-09-08 Behringwerke Ag IMMUNOGENIC FUSION PROTEINS CONTAINING EPSTEIN BARR VIRUS PROTEINS

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BAYLIS,S.A. ET AL.: "High-level expression of the Epstein-Barr Virus Alkaline desoxyribonuclease using a recombinant baculovirus: application to the diagnosis of nasopharyngeal carcinoma", VIROLOGY, vol. 181, no. 1, March 1991 (1991-03-01), ORLANDO US, pages 390 - 394, XP000671825 *
FRAPPIER, L. & O'DONNELL M.: "Overproduction, purification, and characterization of EBNA1, the origin binding protein of Epstein-Barr virus", JOURNAL OF BIOLOGICAL CHEMISTRY (MICROFILMS), vol. 266, no. 12, 25 April 1991 (1991-04-25), MD US, pages 7819 - 7826, XP000673408 *
NUEBLING, C.M. ET AL.: "Expression of Epstein-Barr virus membrane antigen gp350/220 in E. coli and in insect cells", VIROLOGY, vol. 191, no. 11, November 1992 (1992-11-01), ORLANDO US, pages 443 - 447, XP000673411 *
SCHUBACH, W.H. ET AL.: "Expression of Epstein-Barr virus Nuclear Antigen 2 in insect cells from a baculovirus vector", VIROLOGY, vol. 185, no. 1, November 1991 (1991-11-01), ORLANDO US, pages 428 - 431, XP000671826 *
See also references of WO9419495A1 *

Also Published As

Publication number Publication date
EP0687308A1 (en) 1995-12-20
WO1994019495A1 (en) 1994-09-01
KR960701218A (en) 1996-02-24
JPH08507681A (en) 1996-08-20
CA2150691A1 (en) 1994-09-01
AU674936B2 (en) 1997-01-16
AU6269394A (en) 1994-09-14

Similar Documents

Publication Publication Date Title
Luka et al. A sensitive enzyme-linked immunosorbent assay (ELISA) against the major EBV-associated antigens. I. Correlation between ELISA and immunofluorescence titers using purified antigens
GB8404368D0 (en) Monoclonal antibodies to human cytomegalovirus
ZA853025B (en) Isolation of proteins of htlv-iii,serological detection of antibodies to htlv-iii in sera of patients with aids and pre-aids conditions,and detection of htlv-iii infection by immuno-assays using htlv-iii and its proteins
Vornhagen et al. Early serodiagnosis of acute human cytomegalovirus infection by enzyme-linked immunosorbent assay using recombinant antigens
EP0284587A3 (en) Synthetic peptide antigens for the detection of hiv-1 infection
AU8849391A (en) An augmented western blot format and immunoassay for detection of viral antibodies
AU7345487A (en) Layered immunoassay using antibodies bound to transport particles to determine the presence of an antigen
AU735981B2 (en) Peptide reagent for the detection of human cytomegalovirus (CMV)
WO1997031117A3 (en) A human cytomegalovirus combined antigen and its use
DK187286A (en) HERPES-VIRUS-SPECIFIC IMMUNOLOGICAL MATERIALS AND METHODS
EP0248534A3 (en) Method of detecting aids virus infection
EP0870199A4 (en) Assays for growth hormone secretagogue receptors
EP0869177A3 (en) Human a- and b- platelet-derived growth factor receptor proteins and uses therefor.
IE860315L (en) Detecting htlv-iii neutralising antibodies
WO1995016040A3 (en) Immunofluorescence assay for the detection of antibodies using recombinant antigens in insoluble form
AU7737091A (en) Immunodiagnostic assay for rheumatoid arthritis
EP0335134A3 (en) Mouse monoclonal antibody to human immunodeficiency virus gp41 protein
EP0504388A4 (en) Varicella-zoster virus antigen
EP0754755A3 (en) Recombinant autologous Epstein-Barr viral fusion proteins, test kits containing them and methods for the detection of Epstein-Barr virus specific antibodies
EP0238971A3 (en) Antibodies directed to a lymphokine
Spiezia et al. Prevalence of specific antibodies to herpes simplex virus type 2 as revealed by an enzyme-linked immunoassay and Western blot analysis
KR960701218A (en) RECOMB INANT EPSTEIN-BARR VIRAL CAPSID ANTIGEN USEFUL IN DIAGNOSTIC METHOD
GB2323360A (en) Peptide structures for use in detecting herpes simplex virus type 2
Silvestri et al. Fine specificity and neutralizing activity of human serum antibodies directed to the major antigenic region on gp 116 of human cytomegalovirus
Zal et al. Epitope mapping of mouse monoclonal antibodies to the ppUL83 lower matrix phosphoprotein of human cytomegalovirus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950712

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: C12N 15/86

A4 Supplementary search report drawn up and despatched

Effective date: 19970523

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990901